MN-TRU-VUE
17.11.2021 08:02:11 CET | Business Wire | Press release
Opened Oct. 22, 2021, the new MUNCH Museum in Oslo, Norway, displays the works of Edvard Munch (1863-1944). While Munch produced a large, complex body of work, he is most well-known for “The Scream.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116006464/en/
For the new museum, WERNER MURRER RAHMEN and HALBE Rahmen of Germany created over 500 frames to strict conservation requirements, keeping with the aesthetic of Munch’s style. Tru Vue ® Optium Museum Acrylic ® protects these world-famous artworks with an intimate viewing experience.
To watch a documentary film and learn more about MUNCH Museum’s reframing project, visit https://tru-vue.com/2021/11/new-frames-fitted-with-optium-museum-acrylic-at-munchmuseet/.
MUNCH Museum’s dual-frame system has a visible exterior and a concealed interior.
WERNER MURRER RAHMEN hand-made the outer, decorative wood framing, modeled after extensive historical research on original Munch frames. Munch used simple, wood frames and frequently left his artwork outside to directly interact with nature, resulting in a unique patina.
HALBE Rahmen engineered the vault-like, inner framing with Optium Museum Acrylic and a slim aluminum profile, which is essentially indiscernible beneath the wooden overlay. A magnetic closure allows the artwork to be front-loaded to reduce handling.
“It’s a beautiful system,” praised Barbara De Haan, MUNCH Museum’s relocation project leader. “Frames are extremely important.” Observing one of Munch’s pieces with its new frame and Optium Museum Acrylic, she commented, “It’s perfect. You see how the work comes alive. It speaks to you.”
“It was important that visitors to the new MUNCH Museum could get as close as possible to the artist’s work, to really feel and experience it; all while keeping the works protected,” said Tru Vue director of fine art and museums, Dr. Jennifer Booth. “We don’t want them to notice our product. We want them to get lost in the artwork, to see the texture of the paint, to be carried away in the emotion of the piece, rather than having that barrier.”
“With Optium Museum Acrylic, it is like you are close to the canvas with no glass in front. Glazing is necessary, but it is perfect if you don’t see it,” noted Werner Murrer.
David Halbe added, “The glazing that is in between the artwork and the visitor is very important. It should protect the painting without disturbing the view.”
Johan Øvergård, art technical manager at MUNCH, said, “The advantage of using Tru Vue Optium Museum Acrylic compared to laminated glass is the reduced weight, which eases handling, transporting and installing the artworks.” The system also allows for Munch’s artworks to be loaned internationally.
Serving museums and custom framers worldwide, Tru Vue, Inc. manufacturers UV-protective, anti-reflective, and high-performance glass and acrylic in the U.S.
“The coating process is a combination of a lot of science and a touch of art from our technical teams,” said Nate Soukup, Tru Vue vice president of operations. “We’ve worked tirelessly to perfect the production of Optium® over the last 20 years. We’ve developed the ability to produce acrylic in high volume, large sizes and with extremely tight quality specifications that our customers, like the MUNCH Museum, require.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116006464/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
